Dlx5 Represses the Transcriptional Activity of PPARγ

Biol Pharm Bull. 2021;44(9):1303-1308. doi: 10.1248/bpb.b21-00245.

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a master transcription factor in adipocyte differentiation, while distal-less homeobox 5 (Dlx5) is essential for initiating osteoblast differentiation by driving Runt-related transcription factor 2 expression. Considering that adipocytes and osteoblasts share common progenitors, there is a reciprocal correlation between bone and fat formation. However, the mechanism by which Dlx5 controls PPARγ remains unclear. We elucidated that Dlx5 physically binds to PPARγ during immunoprecipitation; in particular, the ligand-binding and DNA-binding domains of PPARγ were involved in the interaction. Transcriptional activity of PPARγ was significantly decreased by Dlx5 overexpression, whereas the opposite results were detected with Dlx5 knockdown. Rosiglitazone, a PPARγ agonist, further enhanced the PPARγ-induced transcriptional activity; however, Dlx5 overexpression effectively repressed the rosiglitazone-mediated increase in activity. Finally, DNA-binding affinity assay revealed that Dlx5 interrupts the interaction of PPARγ with the PPARγ response element promoter. In conclusion, our findings indicate that Dlx5 impedes PPARγ-induced activity, and it may be useful for managing diabetes drug-mediated obesity.

Keywords: distal-less homeobox 5; peroxisome proliferator-activated receptor γ; transcription.

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / physiology
  • Animals
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Homeodomain Proteins / metabolism*
  • Mice
  • PPAR gamma / agonists
  • PPAR gamma / metabolism*
  • Promoter Regions, Genetic
  • Protein Domains
  • Rosiglitazone / pharmacology
  • Transcriptional Activation

Substances

  • Dlx5 protein, mouse
  • Homeodomain Proteins
  • PPAR gamma
  • Pparg protein, mouse
  • Rosiglitazone